Overview

Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Status:
Terminated
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
This is a phase 3, open-label, multiple-center, non-randomized single dose study to assess the safety and efficacy of [123I]NAV5001 SPECT imaging in aiding in the differentiaion of parkinsonian syndromes from non-parkinsonian tremor.
Phase:
Phase 3
Details
Lead Sponsor:
Navidea Biopharmaceuticals